Naoyuki Nogami

20.5k total citations · 6 hit papers
149 papers, 7.4k citations indexed

About

Naoyuki Nogami is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Naoyuki Nogami has authored 149 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Pulmonary and Respiratory Medicine, 112 papers in Oncology and 30 papers in Molecular Biology. Recurrent topics in Naoyuki Nogami's work include Lung Cancer Treatments and Mutations (107 papers), Lung Cancer Research Studies (54 papers) and Lung Cancer Diagnosis and Treatment (49 papers). Naoyuki Nogami is often cited by papers focused on Lung Cancer Treatments and Mutations (107 papers), Lung Cancer Research Studies (54 papers) and Lung Cancer Diagnosis and Treatment (49 papers). Naoyuki Nogami collaborates with scholars based in Japan, United States and United Kingdom. Naoyuki Nogami's co-authors include Denis Moro‐Sibilot, Francesco Orlandi, Delvys Rodríguez‐Abreu, Fabrice Barlési, Federico Cappuzzo, Robert M. Jotte, Anthony Lee, Daniil Stroyakovskiy, Christian A. Thomas and Martin Reck and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Naoyuki Nogami

141 papers receiving 7.3k citations

Hit Papers

Atezolizumab for First-Line Treatment of Metastatic N... 2013 2026 2017 2021 2018 2019 2018 2013 2017 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    2018 2.6k citations Mark A. Socinski, Robert M. Jotte et al. profile →
  2. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
    2019 688 citations Tony Mok, Makoto Nishio et al. profile →
  3. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
    2018 511 citations Kazuhiko Nakagawa, Naoyuki Nogami et al. Journal of Clinical Oncology profile →
  4. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
    2013 449 citations Takashi Seto, Katsuyuki Kiura et al. profile →
  5. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    2017 380 citations Suresh S. Ramalingam, Chee Khoon Lee et al. Journal of Clinical Oncology profile →
  6. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
    2021 316 citations Mark A. Socinski, Makoto Nishio et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naoyuki Nogami Japan 30 5.9k 5.4k 1.4k 969 757 149 7.4k
Mary J. Fidler United States 22 5.2k 0.9× 3.7k 0.7× 803 0.6× 748 0.8× 1.1k 1.5× 115 6.4k
Caicun Zhou China 39 6.4k 1.1× 6.8k 1.3× 2.6k 1.8× 1.6k 1.7× 601 0.8× 136 8.9k
Martin Sebastian Germany 27 4.1k 0.7× 3.3k 0.6× 1.7k 1.2× 930 1.0× 945 1.2× 117 5.8k
Manuel Cobo Spain 30 3.6k 0.6× 3.4k 0.6× 1.3k 1.0× 1.1k 1.1× 565 0.7× 219 5.3k
Hiroshi Nokihara Japan 40 3.9k 0.7× 3.3k 0.6× 1.7k 1.2× 935 1.0× 484 0.6× 237 5.9k
Jong‐Mu Sun South Korea 44 4.8k 0.8× 4.4k 0.8× 1.5k 1.1× 1.0k 1.1× 657 0.9× 234 7.1k
Andrea Fülöp Hungary 9 7.9k 1.3× 5.3k 1.0× 898 0.6× 1.2k 1.2× 1.8k 2.4× 14 9.2k
Suman Rao United States 10 7.9k 1.4× 5.4k 1.0× 895 0.6× 1.2k 1.2× 1.8k 2.4× 21 9.3k
Michael Smylie Canada 30 7.2k 1.2× 4.4k 0.8× 2.4k 1.8× 1.0k 1.0× 1.6k 2.1× 92 9.1k
Daniil Stroyakovskiy Russia 28 7.2k 1.2× 3.7k 0.7× 2.6k 1.8× 1.2k 1.2× 1.4k 1.8× 114 8.7k

Countries citing papers authored by Naoyuki Nogami

Since Specialization
Citations

This map shows the geographic impact of Naoyuki Nogami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoyuki Nogami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoyuki Nogami more than expected).

Fields of papers citing papers by Naoyuki Nogami

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoyuki Nogami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoyuki Nogami. The network helps show where Naoyuki Nogami may publish in the future.

Co-authorship network of co-authors of Naoyuki Nogami

This figure shows the co-authorship network connecting the top 25 collaborators of Naoyuki Nogami. A scholar is included among the top collaborators of Naoyuki Nogami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoyuki Nogami. Naoyuki Nogami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ohe, Yuichiro, Satoshi Watanabe, Xiubao Ren, et al.. (2024). BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).. Journal of Clinical Oncology. 42(16_suppl). 8001–8001. 15 indexed citations
2.
Nishio, Makoto, Shinji Atagi, Kōichi Goto, et al.. (2023). Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer. Translational Lung Cancer Research. 12(6). 1167–1184. 3 indexed citations
3.
Yoh, Kiyotaka, Takashi Seto, Miyako Satouchi, et al.. (2021). Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. Lung Cancer. 155. 40–45. 17 indexed citations
4.
Horinouchi, Hidehito, Naoyuki Nogami, Hideo Saka, et al.. (2021). Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study. Cancer Science. 112(8). 3255–3265. 40 indexed citations
5.
6.
Reck, Martin, Tony Mok, Mark A. Socinski, et al.. (2020). 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. Annals of Oncology. 31. S837–S838. 12 indexed citations
7.
Tan, Daniel Shao-Weng, M-J. Ahn, Herbert H. Loong, et al.. (2020). 299MO Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC. Annals of Oncology. 31. S1358–S1359. 2 indexed citations
8.
Nakahara, Yoshiro, Tsuneo Shimokawa, Naoyuki Nogami, et al.. (2020). Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913. Investigational New Drugs. 39(1). 202–209. 2 indexed citations
9.
Horinouchi, Hidehito, Naoyuki Nogami, Hideo Saka, et al.. (2019). Safety/Tolerability of 1L Pembrolizumab+Chemotherapy in Japanese Patients with Metastatic Nonsquamous NSCLC: KEYNOTE-189. 3–9.
10.
Kanai, Kuninobu, Nobuyuki Yamamoto, Naoyuki Nogami, et al.. (2018). 141PD A prospective study of molecular testing status in the EGFR mutation positive NSCLC patients with disease progression during EGFR TKI treatment (REMEDY study). Journal of Thoracic Oncology. 13(4). S82–S83. 4 indexed citations
11.
Reck, Martin, Mark A. Socinski, Federico Cappuzzo, et al.. (2017). Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150). Annals of Oncology. 28. xi31–xi31. 32 indexed citations
12.
Hotta, Katsuyuki, Keisuke Aoe, Toshiyuki Kozuki, et al.. (2017). A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(2). 273–279. 123 indexed citations
13.
Nakagawa, Kazuhiko, Terufumi Kato, Toshiaki Takahashi, et al.. (2017). P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050). Journal of Thoracic Oncology. 12(11). S2229–S2230. 2 indexed citations
14.
Ramalingam, Suresh S., Chee Khoon Lee, Takayasu Kurata, et al.. (2016). LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. Journal of Thoracic Oncology. 11(4). S152–S152. 51 indexed citations
15.
Hotta, Katsuyuki, Jiichiro Sasaki, Sho Saeki, et al.. (2015). Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non–Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. Clinical Lung Cancer. 17(1). 75–79. 11 indexed citations
16.
Murakami, Haruyasu, Nobuyuki Yamamoto, Taro Shibata, et al.. (2014). A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer. 84(1). 67–72. 53 indexed citations
17.
Kawahara, Masaaki, Shinji Atagi, Kiyoshi Komuta, et al.. (2013). Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.. PubMed. 33(10). 4631–7. 6 indexed citations
18.
Hotta, Katsuyuki, Katsuyuki Kiura, Nagio Takigawa, et al.. (2010). Desire for Information and Involvement in Treatment Decisions: Lung Cancer Patients' Preferences and Their Physicians' Perceptions: Results from Okayama Lung Cancer Study Group Trial 0705. Journal of Thoracic Oncology. 5(10). 1668–1672. 18 indexed citations
19.
Yoshioka, Takashi, Shingo Harita, Shoichi Kuyama, & Naoyuki Nogami. (2007). A Case of Pulmonary Adenocarcinoma Followed by Computed Tomography for 11 Years. Haigan. 47(4). 343–346. 3 indexed citations
20.
Nogami, Naoyuki, M Matsuno, Takashi Hara, et al.. (2006). Elimination of the Allergenicity of Food Protein by High Pressure. The Review of High Pressure Science and Technology. 16(1). 11–16. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary J. Fidler Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Martin Sebastian Breakdown of academic impact, for papers by Manuel Cobo Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Jong‐Mu Sun Breakdown of academic impact, for papers by Andrea Fülöp Breakdown of academic impact, for papers by Suman Rao Breakdown of academic impact, for papers by Michael Smylie Breakdown of academic impact, for papers by Daniil Stroyakovskiy
Rankless by CCL
2026